Tom M. Ganten

3.9k total citations
68 papers, 2.0k citations indexed

About

Tom M. Ganten is a scholar working on Hepatology, Molecular Biology and Epidemiology. According to data from OpenAlex, Tom M. Ganten has authored 68 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 24 papers in Molecular Biology and 20 papers in Epidemiology. Recurrent topics in Tom M. Ganten's work include Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Cell death mechanisms and regulation (12 papers) and Liver Disease and Transplantation (11 papers). Tom M. Ganten is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Cell death mechanisms and regulation (12 papers) and Liver Disease and Transplantation (11 papers). Tom M. Ganten collaborates with scholars based in Germany, United States and United Kingdom. Tom M. Ganten's co-authors include Ronald Koschny, Henning Walczak, Wolfgang Stremmel, Tobias L. Haas, Jaromir Sykora, Martin R. Sprick, Kerstin Herzer, Henning Schulze‐Bergkamen, Min Li‐Weber and Peter Büchler and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Tom M. Ganten

67 papers receiving 2.0k citations

Peers

Countries citing papers authored by Tom M. Ganten

Since Specialization

Citations

This map shows the geographic impact of Tom M. Ganten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom M. Ganten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom M. Ganten more than expected).

Fields of papers citing papers by Tom M. Ganten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom M. Ganten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom M. Ganten. The network helps show where Tom M. Ganten may publish in the future.

Co-authorship network of co-authors of Tom M. Ganten

This figure shows the co-authorship network connecting the top 25 collaborators of Tom M. Ganten. A scholar is included among the top collaborators of Tom M. Ganten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom M. Ganten. Tom M. Ganten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases 2014 ·Langenbeck s Archives of Surgery ·Katrin Hoffmann, Ulf Hinz, (unknown), Tom M. Ganten, Daniel Gotthardt, Thomas Longerich, Peter Schirmacher, Peter Schemmer	7
2	Improvement in Gastrointestinal and Health-related Quality of Life Outcomes After Conversion From Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium in Liver Transplant Recipients 2014 ·Transplantation Proceedings ·Martina Sterneck, Utz Settmacher, Tom M. Ganten, Christoph Sarrazin, Nicola Speidel, (unknown), Nils Heyne, Eva‐Maria Paulus, (unknown), Lutz Fischer	12
3	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection 2013 ·Pathology - Research and Practice ·(unknown), Anna Zimmermann, Ronald Koschny, Jaromir Sykora, Wolfgang Stremmel, Peter Schirmacher, Henning Walczak, Tom M. Ganten	8
4	Transvaskuläre Ablation des hepatozellulären Karzinoms 2012 ·Der Radiologe ·Boris Radeleff, Ulrike Stampfl, Christof M. Sommer, Nadine Bellemann, Katrin Hoffmann, Tom M. Ganten, Robert Ehehalt, Hans‐Ulrich Kauczor	3
5	Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib 2012 ·European Journal of Radiology ·Xu Dai, Heinz-Peter Schlemmer, Bernhard Schmidt, (unknown), Ke Xu, Tom M. Ganten, Maria‐Katharina Ganten	66
6	Systemische Amyloidosen 2011 ·Der Internist ·Stefan Schönland, Norbert Blank, Arnt V. Kristen, Jörg Beimler, Tom M. Ganten, Ute Hegenbart	1
7	Risk factors of survival after liver transplantation for HCC: a multivariate single‐center analysis 2011 ·Clinical Transplantation ·Katrin Hoffmann, Ulf Hinz, (unknown), Boris Radeleff, Tom M. Ganten, Peter Schirmacher, Jan Schmidt, Markus W. Büchler, Peter Schemmer	22
8	Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: Bare metal stents (BMS) versus viatorr stent-grafts (VSG) 2011 ·European Journal of Radiology ·Christof M. Sommer, (unknown), Ulrike Stampfl, Nadine Bellemann, Peter Sauer, Tom M. Ganten, Juergen Weitz, Hans‐Ulrich Kauczor, Boris Radeleff	43
9	LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS : AN ANALYSIS OF MEDICAL AND SURGICAL RISK FACTORS 2010 ·Transplant International ·Nadine Pannicke, (unknown), Martina Sterneck, Christine zu Eulenburg, Tom M. Ganten, Peter Sauer, Marcus Schuchmann, Ansgar W. Lohse, Christoph Schramm	2
10	Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis 2009 ·Journal of Neuro-Oncology ·Ronald Koschny, Heidrun Holland, Jaromir Sykora, (unknown), Wolfgang Krupp, Manfred Bauer, (unknown), Peter Ahnert, Jürgen Meixensberger, Wolfgang Stremmel, Henning Walczak, Tom M. Ganten	17
11	Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer 2009 ·Journal of Molecular Medicine ·Tom M. Ganten, Jaromir Sykora, Ronald Koschny, (unknown), Sebastian Aulmann, Ulrich Mansmann, Wolfgang Stremmel, Hans‐Peter Sinn, Henning Walczak	69
12	TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics 2009 ·Advances in experimental medicine and biology ·Christina Falschlehner, Tom M. Ganten, Ronald Koschny, Uta Schaefer, Henning Walczak	83
13	Chronic anemia masking a primary large B-cell lymphoma of the small intestine, finally diagnosed by double-balloon enteroscopy 2008 ·Endoscopy ·Kilian Weigand, Tom M. Ganten, Mindaugas Andrulis, Wolfgang Stremmel, Pieter J.J. Sauer, Anja Schaible	2
14	[¹⁸F]-FDG-PET in der Diagnostik gastrointestinaler Tumoren 2008 ·Zeitschrift für Gastroenterologie ·Inga Buchmann, Tom M. Ganten, Uwe Haberkorn	8
15	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window 2007 ·Hepatology ·Ronald Koschny, Tom M. Ganten, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Armin Kolb, Wolfgang Stremmel, Henning Walczak	102
16	Helicobacter pylori‐induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors 2007 ·European Journal of Clinical Investigation ·Tom M. Ganten, (unknown), J Sýkora, Ronald Koschny, (unknown), Jochen Rudi, Wolfgang Stremmel, Henning Walczak	17
17	Cytogenetic and molecular biological characterization of an adult medulloblastoma 2007 ·Cancer Genetics and Cytogenetics ·Heidrun Holland, Ronald Koschny, Wolfgang Krupp, Jürgen Meixensberger, Manfred Bauer, R. Schober, Holger Kirsten, Tom M. Ganten, Peter Ahnert	7
18	The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab 2006 ·Cytotherapy ·Martin Kornacker, Michael R. Verneris, (unknown), Tom M. Ganten, Christian Scheffold, Robert S. Negrin	6
19	Proteasome Inhibition Sensitizes Hepatocellular Carcinoma Cells, But Not Human Hepatocytes, to TRAIL * 2005 ·Hepatology ·Tom M. Ganten, Ronald Koschny, Tobias L. Haas, Jaromir Sykora, Min Li‐Weber, Kerstin Herzer, Henning Walczak	142
20	Emergence of oligoclonal t cell populations following therapeutic t cell depletion in rheumatoid arthritis 1995 ·Arthritis & Rheumatism ·M. C. Jendro, Tom M. Ganten, Eric L. Matteson, Cornelia M. Weyand, Jörg J. Goronzy	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact